Citations (61)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Samaneh Kalirai, Jasmina I Ivanova, Magaly Perez-Nieves, Judith J Stephenson, Irene Hadjiyianni, Michael Grabner, Roy Daniel Pollom, Caroline Geremakis, Beverly L Reed & Lawrence Fisher. (2020) Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States. Diabetes, Metabolic Syndrome and Obesity 13, pages 1023-1033.
Read now
Read now
Theresa L. Garnero, Nichola J. Davis, Magaly Perez-Nieves, Irene Hadjiyianni, Dachuang Cao, Jasmina I. Ivanova & Mark Peyrot. (2018) Insulin non-persistence among people with type 2 diabetes: how to get your patients to stay on insulin therapy. Postgraduate Medicine 130:4, pages 394-401.
Read now
Read now
Xiaoning He, Liming Chen, Ke Wang, Haiya Wu & Jing Wu. (2017) Insulin adherence and persistence among Chinese patients with type 2 diabetes: a retrospective database analysis. Patient Preference and Adherence 11, pages 237-245.
Read now
Read now
Mark Peyrot, Magaly Perez-Nieves, Jasmina Ivanova, Dachuang Cao, Luke Schmerold, Samaneh Kalirai & Irene Hadjiyianni. (2017) Correlates of basal insulin persistence among insulin-naïve people with type 2 diabetes: results from a multinational survey. Current Medical Research and Opinion 33:10, pages 1843-1851.
Read now
Read now
Magaly Perez-Nieves, Jasmina I. Ivanova, Irene Hadjiyianni, Chen Zhao, Dachuang Cao, Luke Schmerold, Samaneh Kalirai, Sarah King, Amy M. DeLozier, Howard G. Birnbaum & Mark Peyrot. (2017) Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey. Current Medical Research and Opinion 33:10, pages 1833-1842.
Read now
Read now
Magaly Perez-Nieves, Samaneh Kabul, Urvi Desai, Jasmina I. Ivanova, Noam Y. Kirson, Alice Kate Cummings, Howard G. Birnbaum, Ran Duan, Dachuang Cao & Irene Hadjiyianni. (2016) Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US. Current Medical Research and Opinion 32:4, pages 669-680.
Read now
Read now
Davida F Kruger, Susan LaRue & Phil Estepa. (2015) Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment. Diabetes, Metabolic Syndrome and Obesity 8, pages 49-56.
Read now
Read now
Gérard Reach. (2014) Patient autonomy in chronic care: solving a paradox. Patient Preference and Adherence 8, pages 15-24.
Read now
Read now
Gérard Reach, Véronique Le Pautremat & Shaloo Gupta. (2013) Determinants and consequences of insulin initiation for type 2 diabetes in France: analysis of the National Health and Wellness Survey. Patient Preference and Adherence 7, pages 1007-1023.
Read now
Read now
Stuart A. Ross, Hugh D. Tildesley & John Ashkenas. (2011) Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Current Medical Research and Opinion 27:sup3, pages 13-20.
Read now
Read now
Edward S. Kimball & Mark Aagren. (2011) Coverage of insulin delivery devices and basal insulin analogs by US managed care organizations. Journal of Medical Economics 14:6, pages 720-728.
Read now
Read now
Machaon MK Bonafede, Anupama Kalsekar, Manjiri Pawaskar, Kimberly M Ruiz, Amelito M Torres, Karen R Kelly & Suellen M Curkendall. (2010) A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures. Patient Preference and Adherence 4, pages 147-156.
Read now
Read now
Marco daCosta DiBonaventura, Jan-Samuel Wagner, Cynthia J Girman, Kimberly Brodovicz, Qiaoyi Zhang, Ying Qiu, Sri-Ram Pentakota & Larry Radican. (2010) Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication. Patient Preference and Adherence 4, pages 397-406.
Read now
Read now
Articles from other publishers (48)
Paschalis Karakasis, Dimitrios Patoulias, Konstantinos Pamporis, Panagiotis Stachteas, Konstantinos I. Bougioukas, Aleksandra Klisic, Nikolaos Fragakis & Manfredi Rizzo. (2023) Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials. Metabolism 149, pages 155710.
Crossref
Crossref
Aditi R. Saxena, Juan P. Frias, Lisa S. Brown, Donal N. Gorman, Szilard Vasas, Nikolaos Tsamandouras & Morris J. Birnbaum. (2023) Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes. JAMA Network Open 6:5, pages e2314493.
Crossref
Crossref
Soumyabrata RoyChaudhuri, Anirban Majumder, Debmalya Sanyal, Soma Chakraborty & Susama Chuyan. (2023) Early Insight Into the Retrospective Data of a Case Series on Type 2 Diabetes Mellitus on Alternate-Day Dosing of Oral Semaglutide: Utopia or Reality?. Cureus.
Crossref
Crossref
Shashank R. Joshi, Rajesh Rajput, Subhankar Chowdhury, Awadhesh K. Singh, Ganapathi Bantwal, Ashok K. Das, A.G. Unnikrishnan, Banshi D. Saboo, Jothydev Kesavadev, Samit Ghosal & Viswanathan Mohan. (2022) The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16:6, pages 102508.
Crossref
Crossref
Juris J. Meier, Charlotte Granhall, Ulrike Hoevelmann, Andrea Navarria, Leona Plum‐Moerschel, Chethana Ramesh, Andrea Tannapfel & Christoph Kapitza. (2022) Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes. Diabetes, Obesity and Metabolism 24:4, pages 684-692.
Crossref
Crossref
Qiming Tan, Seun E. Akindehin, Camila E. Orsso, Richelle C. Waldner, Richard D. DiMarchi, Timo D. Müller & Andrea M. Haqq. (2022) Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes. Frontiers in Endocrinology 13.
Crossref
Crossref
Lucia Brodosi, Salvatore Petta, Maria L. Petroni, Giulio Marchesini & Maria C. Morelli. (2021) Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients. Transplantation 106:3, pages 462-478.
Crossref
Crossref
Paulina K. Wrzal, Amir A. Mohseni, Carl Fournier, Ronald Goldenberg, Debbie Hollahan, Susie Jin, Sue D. Pedersen, Michael Vallis, Andrean Bunko, Varun Myageri, Atif Kukaswadia, Calum S. Neish & Noah M. Ivers. (2022) Persons With Diabetes and General/Family Practitioner Perspectives Related to Therapeutic Inertia in Type 2 Diabetes Mellitus Using Qualitative Focus Groups and the Theoretical Domains Framework: Results From the MOTION Study. Canadian Journal of Diabetes 46:2, pages 171-180.
Crossref
Crossref
Awadhesh Kumar Singh, Ritu Singh & Anoop Misra. (2022) Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16:3, pages 102436.
Crossref
Crossref
Rajesh Rajput, Sujoy Ghosh, Samar Banerjee, Beena Bansal, Manoj Chawla, AbhayI Ahluwalia, Tejal Lathia & AshokK Das. (2022) First-in-class oral semaglutide: Overcoming barriers of incretinisation in the Indian context. Indian Journal of Endocrinology and Metabolism 26:5, pages 417.
Crossref
Crossref
Anastasia-Stefania Alexopoulos, William S Yancy, David Edelman, Cynthia J Coffman, Amy S Jeffreys, Matthew L Maciejewski, Corrine I Voils, Nicole Sagalla, Anna Barton Bradley, Moahad Dar, Stéphanie B Mayer & Matthew J Crowley. (2019) Clinical associations of an updated medication effect score for measuring diabetes treatment intensity. Chronic Illness 17:4, pages 451-462.
Crossref
Crossref
Tine A. Bækdal, Astrid Breitschaft, Morten Donsmark, Stine J. Maarbjerg, Flemming L. Søndergaard & Jeanett Borregaard. (2021) Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation. Diabetes Therapy 12:7, pages 1915-1927.
Crossref
Crossref
Aditi R. Saxena, Donal N. Gorman, Ryan M. Esquejo, Arthur Bergman, Kristin Chidsey, Clare Buckeridge, David A. Griffith & Albert M. Kim. (2021) Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial. Nature Medicine 27:6, pages 1079-1087.
Crossref
Crossref
Mingmin Zhao, Kreshnik Hoti, Hao Wang, Aniruddh Raghu & Dina Katabi. (2021) Assessment of medication self-administration using artificial intelligence. Nature Medicine 27:4, pages 727-735.
Crossref
Crossref
Fu-Shun Yen, James Cheng-Chung Wei, Jia-Sin Liu, Chih-Cheng Hsu & Chii-Min Hwu. (2020) The factors associated with insulin nonpersistence in persons with type 2 diabetes. Diabetes Research and Clinical Practice 167, pages 108356.
Crossref
Crossref
Jieling Chen, Christi Y. Kao, Xuanyao He, Ludi Fan, Jeffrey A. Jackson & Rattan Juneja. (2020) Treatment Patterns, Adherence, and Persistence Associated With Human Regular U-500 Insulin: A Real-World Evidence Study. Diabetes Spectrum 33:3, pages 264-272.
Crossref
Crossref
Kun‐Ho Yoon, Jahoon Kang, Se Chang Kwon, Michael E. Trautmann, Marcus Hompesch, John Stewart & Christopher H. Sorli. (2020) Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 22:8, pages 1292-1301.
Crossref
Crossref
Björn Eliasson, Jan Ekelund, Mervete Miftaraj, Mattis Flyvholm Ranthe, Ann-Charlotte Mårdby, João Diogo Da Rocha Fernandes & Ann-Marie Svensson. (2020) Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden. Diabetes Therapy 11:8, pages 1807-1820.
Crossref
Crossref
Stefano Del Prato, Jahoon Kang, Michael E. Trautmann, John Stewart, Christopher H. Sorli, Michael Derwahl, Alfonso Soto & Kun‐Ho Yoon. (2020) Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study. Diabetes, Obesity and Metabolism 22:7, pages 1176-1186.
Crossref
Crossref
Sarah L. Anderson, Trevor R. Beutel & Jennifer M. Trujillo. (2020) Oral semaglutide in type 2 diabetes. Journal of Diabetes and its Complications 34:4, pages 107520.
Crossref
Crossref
Puhong Zhang, Heng Zhang, Xian Li, Minyuan Chen, Du Wang & Linong Ji. (2020) Factors and outcomes associated with discontinuation of basal insulin therapy in patients with type 2 diabetes mellitus. Endocrinology, Diabetes & Metabolism 3:2.
Crossref
Crossref
Steven V. EdelmanAnastasia ErmakovaYan XiongRay SieradzanStephanie D. Taylor. (2019) Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study. Journal of Managed Care & Specialty Pharmacy 25:12, pages 1420-1431.
Crossref
Crossref
Tine A. Bækdal, Jeanett Borregaard, Cilie W. Hansen, Mette Thomsen & Thomas W. Anderson. (2019) Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects. Clinical Pharmacokinetics 58:9, pages 1193-1203.
Crossref
Crossref
Mansoor HusainAndreas L. BirkenfeldMorten DonsmarkKathleen DunganFreddy G. EliaschewitzDenise R. FrancoOle K. JeppesenIldiko LingvayOfri MosenzonSue D. PedersenCees J. TackMette ThomsenTina VilsbøllMark L. WarrenStephen C. Bain. (2019) Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine 381:9, pages 841-851.
Crossref
Crossref
Iskandar Idris, Kunal Gulati, Magaly Perez-Nieves, Irene Hadjiyianni, Dachuang Cao, Arash Tahbaz, Jasmina Ivanova & Syed Wasi Hassan. (2019) Associated factors that influenced persistence with basal analog insulin therapy among people with type 2 diabetes: An exploratory analysis from a UK real-world sample. Primary Care Diabetes 13:2, pages 106-112.
Crossref
Crossref
Stephen C. Bain, Ofri Mosenzon, Rosario Arechavaleta, Pawel Bogdański, Abdurrahman Comlekci, Agostino Consoli, Chaicharn Deerochanawong, Kathleen Dungan, Maria C. Faingold, Michael E. Farkouh, Denise R. Franco, Jeppe Gram, Cristian Guja, Pankaj Joshi, Rachid Malek, Juan F. Merino-Torres, Michael A. Nauck, Sue D. Pedersen, Wayne H. -H. Sheu, Robert J. Silver, Cees J. Tack, Nikhil Tandon, Ole K. Jeppesen, Mette Strange, Mette Thomsen & Mansoor Husain. (2019) Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes, Obesity and Metabolism 21:3, pages 499-508.
Crossref
Crossref
Olesya Y. Gurova, Valentin V. Fadeev & Ekaterina S. Maloletkina. (2019) Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence. Diabetes mellitus 21:6, pages 524-533.
Crossref
Crossref
Emma D. Deeks. (2019) Exenatide extended-release pre-filled pen (Bydureon® BCise®): a profile of its use. Drugs & Therapy Perspectives 35:2, pages 51-57.
Crossref
Crossref
Stephen T. Buckley, Tine A. BækdalAndreas VeggeStine J. MaarbjergCharles PykeJonas Ahnfelt-RønneKim G. Madsen, Susanne G. Schéele, Tomas AlanentaloRikke K. KirkBetty L. PedersenRikke B. SkyggebjergAndrew J. Benie, Holger M. StraussPer-Olof Wahlund, Simon BjerregaardErzsébet FarkasCsaba Fekete, Flemming L. SøndergaardJeanett BorregaardMarie-Louise Hartoft-NielsenLotte Bjerre Knudsen. (2018) Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine 10:467.
Crossref
Crossref
Fang Liz Zhou, Lin Xie, Chunshen Pan, Yuexi Wang, Neel Vaidya, Fen Ye, Ronald Preblick & Luigi Meneghini. (2018) Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiating basal insulin. Diabetes, Obesity and Metabolism 20:5, pages 1298-1301.
Crossref
Crossref
Samaneh Kalirai, Ran Duan, Dongju Liu & Beverly L. Reed. (2017) Economic Impact of Treatment Duration and Persistence with Basal Insulin in Previously Insulin-Naive Users. Journal of Managed Care & Specialty Pharmacy 23:3, pages 327-336.
Crossref
Crossref
Irene Hadjiyianni, Urvi Desai, Shuichi Suzuki, Jasmina I. Ivanova, Dachuang Cao, Noam Y. Kirson, Dai Chida, Caroline Enloe, Howard G. Birnbaum & Magaly Perez-Nieves. (2016) Basal Insulin Persistence, Associated Factors, and Outcomes After Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan. Diabetes Therapy 8:1, pages 149-166.
Crossref
Crossref
David D. Schwartz, Sean D. Stewart, James E. Aikens, Jennifer K. Bussell, Chandra Y. Osborn & Monika M. Safford. (2017) Seeing the Person, Not the Illness: Promoting Diabetes Medication Adherence Through Patient-Centered Collaboration. Clinical Diabetes 35:1, pages 35-42.
Crossref
Crossref
Samuel StolpeMichel A. KroesNeil WebbTami Wisniewski. (2016) A Systematic Review of Insulin Adherence Measures in Patients with Diabetes. Journal of Managed Care & Specialty Pharmacy 22:11, pages 1224-1246.
Crossref
Crossref
Ronan Roussel, Bernard Charbonnel, Mourad Behar, Julie Gourmelen, Corinne Emery & Bruno Detournay. (2016) Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study. Diabetes Therapy 7:3, pages 537-549.
Crossref
Crossref
C. Victor Spain, Jonathon J. Wright, Rebecca M. Hahn, Ashley Wivel & Alan A. Martin. (2016) Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes. Clinical Therapeutics 38:7, pages 1653-1664.e1.
Crossref
Crossref
Simon Zhornitsky, Jamie Greenfield, Marcus W. Koch, Scott B. Patten, Colleen Harris, Winona Wall, Katayoun Alikhani, Jodie Burton, Kevin Busche, Fiona Costello, Jeptha W. Davenport, Scott E. Jarvis, Dina Lavarato, Helene Parpal, David G. Patry, Michael Yeung & Luanne M. Metz. (2015) Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study. PLOS ONE 10:4, pages e0123824.
Crossref
Crossref
Robert R. Henry, Julio Rosenstock, Douglas Logan, Thomas Alessi, Kenneth Luskey & Michelle A. Baron. (2014) Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. Journal of Diabetes and its Complications 28:3, pages 393-398.
Crossref
Crossref
Wenhui Wei, Chunshen Pan, Lin Xie & Onur Baser. (2014) Real-World Insulin Treatment Persistence among Patients with Type 2 Diabetes. Endocrine Practice 20:1, pages 52-61.
Crossref
Crossref
Manjiri Pawaskar, Machaon Bonafede, Barbara Johnson, Robert Fowler, Gregory Lenhart & Byron Hoogwerf. (2013) Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study. BMC Endocrine Disorders 13:1.
Crossref
Crossref
Luis-Emilio García-Pérez, María Álvarez, Tatiana Dilla, Vicente Gil-Guillén & Domingo Orozco-Beltrán. (2013) Adherence to Therapies in Patients with Type 2 Diabetes. Diabetes Therapy 4:2, pages 175-194.
Crossref
Crossref
Robert R. Henry, Julio Rosenstock, Douglas K. Logan, Thomas R. Alessi, Kenneth Luskey & Michelle A. Baron. (2013) Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes. Diabetes Care 36:9, pages 2559-2565.
Crossref
Crossref
Robert R. Henry, Douglas Logan, Thomas Alessi & Michelle A. Baron. (2013) A Randomized, Open-Label, Multicenter, 4-Week Study to Evaluate the Tolerability and Pharmacokinetics of ITCA 650 in Patients With Type 2 Diabetes☆☆This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.. Clinical Therapeutics 35:5, pages 634-645.e1.
Crossref
Crossref
J. H. Best, K. Lavillotti, M. B. DeYoung & L. P. Garrison. (2011) The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review. Diabetes, Obesity and Metabolism 14:5, pages 387-398.
Crossref
Crossref
G.C. Hall, A.D. McMahon, M.-P. Dain & P.D. Home. (2011) A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes. Diabetes Research and Clinical Practice 94:3, pages 442-448.
Crossref
Crossref
Stephen N. Davis, Wenhui Wei & Satish Garg. (2011) Clinical Impact of Initiating Insulin Glargine Therapy with Disposable Pen Versus Vial in Patients with Type 2 Diabetes Mellitus in a Managed Care Setting. Endocrine Practice 17:6, pages 845-852.
Crossref
Crossref
Ronald J. PettisBarry GinsbergLaurence HirschDiane SutterSteven KeithElaine McVeyNoel G. HarveyMarcus HompeschLeszek NosekChristoph KapitzaLutz Heinemann. (2011) Intradermal Microneedle Delivery of Insulin Lispro Achieves Faster Insulin Absorption and Insulin Action than Subcutaneous Injection. Diabetes Technology & Therapeutics 13:4, pages 435-442.
Crossref
Crossref
Martin Pfohl, Franz-Werner Dippel, Karel Kostev, Sabine Fuchs & Wioletta Kotowa. (2011) Basal Supported Oral Therapy with Insulin Glargine Results in Longer Persistence and Lower Costs Compared with Insulin Detemir in Type 2 Diabetics in Germany. Health Outcomes Research in Medicine 2:1, pages e39-e50.
Crossref
Crossref